Join host Lauren Hawker Zafer as she engages in a riveting discussion with Dave Latshaw, Ph.D., MBA a visionary leader renowned for his groundbreaking work at Johnson & Johnson and founding BioPhy.
Together, they unravel the complexities of integrating AI into the life sciences and biotechnology sectors, exploring topics ranging from cost-saving implementations to ethical considerations in drug development.
This episode is a must-listen for entrepreneurs, healthcare professionals, and AI enthusiasts eager to understand the transformative potential and ethical implications of AI in shaping the future of healthcare and drug development.
Who is Dave Latshaw, Ph.D., MBA?
Dave received his Ph.D. in chemical and biomolecular engineering from North Carolina State University and went on to get his MBA at Wharton. He began his career at The Janssen Pharmaceutical Companies of Johnson and Johnson, working in a group that was responsible for overseeing the manufacturing of large molecule antibodies, and was the youngest person ever to lead an AI research group at J&J.
Dave also led flagship programs for the company’s AI Advanced Center of Excellence, and enabled J&J’s billion dose commitment during the COVID pandemic. Before leaving J&J and pursuing his MBA, Dave was inducted into Frontiers of Engineering, an organization created by the National Academy of Engineering to recognize top early-career engineers.
While studying at Wharton, the idea of BioPhy originated and later evolved into a life sciences health tech company in 2020. Dave examines opportunities down to first principles using a blend of business acumen, analytics, and the scientific process to use artificial intelligence and biophysics concepts to bring value to the healthcare value chain.
